Breast Cancer Clinical Trials & Research at Providence Medical Group
In the U.S., breast cancer is the second most common cancer in women after
skin cancer. It can occur in both men and women. The most common type
of breast cancer is ductal carcinoma, which begins in the cells of the
ducts. Breast cancer can also begin in the cells of the lobules and in
other tissues in the breast. Invasive breast cancer is breast cancer that
has spread from where it began in the ducts or lobules to surrounding tissue.
Providence Medical Group is currently enrolling patients for the following
breast cancer clinical trials:
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy
of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus
Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic
Triple-Negative Breast Cancer
Treatment agent: Magrolimab + Nap-Paclitaxel or Paclitaxel vs. Nab-Paxlitaxel
or Paclitaxel
PI: Jarrod Holmes, MD
Study Coordinator: Teresa Lund
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04958785?term=NCT04958785&draw=2&rank=1
Sponsor: Gilead Sciences
A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally
Recurrent Breast Cancer Patients in Combination with Pembrolizumab (BriaCell Rollover)
Treatment agent: SV-BR-1-GM + Pembrolizumab
PI:
Jarrod Holmes, MD
Study Coordinator: Kim
Resources and Links:
clinicaltrials.gov NCT No: NCT03328026
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and
Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable
and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless
of Tumor Histology
Treatment agent: Trastuzumab Deruxtecan
PI:
Ian Anderson, MD
Study Coordinator: Camille Shaffer //
Camille.Shaffer@stjoe.org // (707) 521-3809 ext. 1182
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04639219?term=04639219&draw=2&rank=1
Sponsor: AstraZeneca
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan
(T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone
Receptor Positive Breast Cancer Patients whose Disease has Progressed
on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
Treatment agent: Trastuzumab deruxtecan
PI: Manasa Vulshi, MD
Study Coordinator: Camille Shaffer //
Camille.Shaffer@stjoe.org // (707) 521-3809 ext. 1182
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04494425?term=04494425&draw=2&rank=1
Sponsor: AstraZeneca
Study to Assess the Effect of PF_06946860 on Appetite Following Subcutaneous
Administration to Patients with Anorexia and Advanced Cancer
Treatment agent: PF-06946860
PI: Sara Keck, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707)
521-3833 ext. 1313
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04803305?term=PF-06946860&draw=2&rank=2
Sponsor: Pfizer
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and
Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable
and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless
of Tumor Histology
Treatment agent: Berzosertib, Topotecan Hydrochloride
PI:
Ian Anderson, MD
Study Coordinator: Camille Shaffer
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04639219?term=04639219&draw=2&rank=1
Sponsor: AstraZeneca